Cigna’s Demonstration of “Real World” Effectiveness for Hepatitis C New Drug Therapies Drives Affordability Strategies
Cigna is monitoring the health outcomes of customers with hepatitis C who have undergone treatment using a prescription combination with the drug Sovaldi. Cigna found that 91.1% of customers achieved a sustained virologic response. Cigna is taking several steps to try to address the affordability issue, including:.
This article is available to Insider Pro subscribers only.Sign in or register to be an Insider Pro and access ALL LOCKED articles.
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News